Search
Zucapsaicin
go.drugbank.com/drugs/DB09120ApprovedWithdrawnZucapsaicin was approved by the Health Canada in 2010 as topical cream marketed under the brand name Zuacta but currently not FDA-approved. … Zucapsaicin has also been evaluated for the management of several conditions manifested by chronic nerve pain.
Arimoclomol
go.drugbank.com/drugs/DB05025Approved[L51384] Arimoclomol was approved by the FDA on September 20, 2024, making it the first treatment for Niemann-Pick disease, type C (NPC).
Human calcitonin
go.drugbank.com/drugs/DB06773ApprovedCalcitonin was first discovered in isolated parathyroid tissue as a substance with a serum-calcium-lowering effect. It is constituted as a 32-amino acid single chain polypeptide structure that gets secreted as a regulatory agent in calci...
Esmolol
go.drugbank.com/drugs/DB00187ApprovedInvestigationalWithdrawnIt has a rapid onset but short duration of action without causing significant intrinsic sympathomimetic or membrane stabilizing activities at recommended therapeutic doses. … It works by blocking beta-adrenergic receptors in the heart, which leads to decreased force and rate of heart contractions.
Products: Brevibloc Liq IV 10mg/ml, Brevibloc Injection 10mg/mlImelasomeran
go.drugbank.com/drugs/DB17090ApprovedInvestigationalImelasomeran was first approved in Canada on September 1, 2022, as one-half of Moderna's Spikevax Bivalent COVID-19 mRNA vaccine. It encodes for the viral spike protein of the Omicron BA.1 variant of SARS-CoV-2, a particularly infectious...
Vitamin D
go.drugbank.com/drugs/DB11094ApprovedInvestigationalNutraceuticalVet approvedVitamin D3 and D2 require hydroxylation in order to become biologically active in the human body. … Since vitamin D can be endogenously synthesized in adequate amounts by most mammals exposed to sufficient quantities of sunlight, vitamin D functions like a hormone on vitamin D receptors to regulate calcium
Mixtures: Budpak Vitamin A and DCangrelor
go.drugbank.com/drugs/DB06441ApprovedInvestigationalCangrelor was approved by the FDA in June 2015 for intravenous application. … Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors.
Anakinra
go.drugbank.com/drugs/DB00026ApprovedInvestigationalOn November 14, 2001, it was approved by the FDA for the treatment of rheumatoid arthritis. … [L35415] Anakinra is indicated for the management of rheumatoid arthritis (RA) in patients 18 years of age or older who have failed one or more disease-modifying antirheumatic drugs (DMARDs), as well as
Piflufolastat F 18
go.drugbank.com/drugs/DB14805ApprovedInvestigational[L34319] The images generated by positron emission tomography (PET) are less detailed than those obtained via MRI or CT, but are more sensitive and can reveal cancerous tissue in any area of the body provided … It was first approved by the FDA in May 2021 under the brand name Pylarify and aims to allow for earlier and more accurate detection of suspected prostate cancer metastases or recurrences.
Indacaterol
go.drugbank.com/drugs/DB05039ApprovedInvestigationalIndacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed. … It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler.